Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 155   

Articles published

NVS 71.92 -1.07 (-1.47%)
price chart
Could Novartis AG (ADR) See a Reversal After Having a Gap Up Today?
The stock of Novartis AG (ADR) (NYSE:NVS) gapped up by $0.17 today and has $109.53 target or 49.00% above today's $73.51 share price.
Analyst's Ratings Review: Novartis AG  CWRU Observer
European stocks for Investors: Novartis AG (ADR) (NVS), National Grid plc (ADR ...
27 reported that it has entered into a worldwide clinical collaboration with Novartis Pharmaceuticals (NVS) to evaluate the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader (SERD), with ...
Novartis AG (ADR) Plunges on Profit Miss
Novartis AG (ADR) (NYSE:NVS) reported lower-than-expected fourth quarter and full year earnings data for fiscal 2015 today, driven mostly by its struggling eye-care business and strengthened dollar.
Large Outflow of Money Witnessed in Novartis AG  Analyst Rating Reports
Novartis Slides 3% Pre-Bell – Q4 Results Miss Views; Expects Flat FY16 Core ...  WallStreet.org
Here's Why Novartis AG (ADR) Fared Better Than Others
Novartis AG ADR (NYSE:NVS) has signed three deals to expand its reach in the immune-oncology market. On Wednesday, Novartis announced that it had acquired Admune Therapeutics, a cancer drug maker.
Novartis (NVS) Strengthens It's Pipeline With Admune Therapeutics & XOMA  CNA Finance (press release)
Hedge Funds Aren't Crazy About Novartis AG (ADR) (NVS) Anymore
We can judge whether Novartis AG (ADR) (NYSE:NVS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas.
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Novartis AG (ADR) to Decline On Q3 Earnings
The share price for Novartis AG ADR (NYSE:NVS) is expected to decline as the drug maker reported lower-than-expected sales and earnings for the third quarter of this fiscal (3QFY15).
Novartis (NVS) Misses on Q3 Earnings, Maintains 2015 View  Zacks.com
Novartis AG (ADR) Entresto Clinches EU approval
Novartis Pharmaceuticals UK's Chief Scientific Officer, Dimitrios Georgiopoulos, says, “Heart failure is a life-threatening condition that leaves a major impact on patients and their carers.
Novartis Gets EU Approval for Cardiovascular Drug Entresto  Zacks.com
Novartis AG (ADR) And Roche May Have To Wait Longer For “Outcome-Based ...
The outcome-based drug pricing model is becoming a dream for Novartis AG (ADR) (NYSE:NVS) and Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY).
Will Novartis And Pharma Giants Provide Alzheimer's Cure?
Novartis AG (ADR) (NYSE:NVS) and other market leaders are trying their best in the development of a novel drug for the comprehensive treatment of Alzheimer's disease.